Oramed Pharmaceuticals (ORMP) Stock Price, News & Analysis

+0.06 (+2.64%)
(As of 04/22/2024 ET)
Today's Range
50-Day Range
52-Week Range
59,020 shs
Average Volume
125,111 shs
Market Capitalization
$94.41 million
P/E Ratio
Dividend Yield
Price Target
ORMP stock logo

About Oramed Pharmaceuticals Stock (NASDAQ:ORMP)

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

ORMP Stock Price History

ORMP Stock News Headlines

ORMP Apr 2024 2.500 put
The A.I. story nobody is telling you (Read ASAP)
There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...
Oramed Pharmaceuticals Inc.: Oramed Letter to Shareholders
Oramed Letter to Shareholders
The A.I. story nobody is telling you (Read ASAP)
There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...
Oramed Pharmaceuticals, Inc.
ORMP: Advancing Development Efforts in China
See More Headlines
Receive ORMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oramed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded


Net Income
$5.53 million
Pretax Margin


Sales & Book Value

Annual Sales
$1.34 million
Book Value
$4.04 per share


Free Float
Market Cap
$94.41 million
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. Nadav Kidron Esq. (Age 50)
    President, CEO & Executive Chairman
    Comp: $754.3k
  • Mr. David Silberman CPA (Age 40)
    CFO & Treasurer
    Comp: $259.53k
  • Dr. Miriam Kidron Ph.D. (Age 84)
    Chief Scientific Officer & Director
    Comp: $503.95k
  • Mr. Joshua Hexter (Age 54)
    Chief Operating & Business Officer
    Comp: $326.94k

ORMP Stock Analysis - Frequently Asked Questions

How have ORMP shares performed in 2024?

Oramed Pharmaceuticals' stock was trading at $2.31 at the beginning of the year. Since then, ORMP shares have increased by 0.9% and is now trading at $2.33.
View the best growth stocks for 2024 here

Are investors shorting Oramed Pharmaceuticals?

Oramed Pharmaceuticals saw a increase in short interest in March. As of March 31st, there was short interest totaling 583,900 shares, an increase of 20.6% from the March 15th total of 484,000 shares. Based on an average trading volume of 174,600 shares, the short-interest ratio is currently 3.3 days.
View Oramed Pharmaceuticals' Short Interest

When is Oramed Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our ORMP earnings forecast

How were Oramed Pharmaceuticals' earnings last quarter?

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) released its earnings results on Wednesday, March, 6th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.12) by $0.04.

What other stocks do shareholders of Oramed Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oramed Pharmaceuticals investors own include Compugen (CGEN), Sarepta Therapeutics (SRPT), Zynerba Pharmaceuticals (ZYNE), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), DURECT (DRRX), OPKO Health (OPK), Pluristem Therapeutics (PSTI) and Palatin Technologies (PTN).

How do I buy shares of Oramed Pharmaceuticals?

Shares of ORMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ORMP) was last updated on 4/23/2024 by Staff

From Our Partners